Insights

More Articles Back to Article

Tocilizumab might improve survival in severe COVID-19

Preliminary data from a study involving 239 COVID-19 patients during the pandemic's early weeks suggest treatment with the cancer drug tocilizumab could improve survival among patients on mechanical ventilators. The survival rate was 75% for those on ventilators who were treated with the drug, compared with survival rates of 10% to 50% reported elsewhere, according to study author Dr. Christina Price, chief of clinical allergy and clinical immunology at Yale New Haven Hospital in Connecticut. HealthDay News (6/23)

Read full article now.

Articles are only one benefit of being a DIA member. Learn more and join today so you don’t miss another article!